Phase I/II/III Pharmacokinetic and Outcome Study of Recombinant Factor IX Product, IB1001, in Subjects with Haemophilia B
Phase of Trial: Phase II/III
Latest Information Update: 28 Mar 2019
Price : $35 *
At a glance
- Drugs Trenonacog alfa (Primary)
- Indications Haemophilia B
- Focus Adverse reactions; First in man; Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Aptevo Therapeutics; Emergent BioSolutions; Inspiration Biopharmaceuticals
- 27 Mar 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 05 Jun 2017 Status changed from active, no longer recruiting to completed.
- 30 Mar 2017 Planned End Date changed from 1 Feb 2017 to 1 May 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History